Mayer Brown, a leading global law firm, secured a victory before the US Court of Appeals for the Federal Circuit on behalf of Valeant International Bermuda in a Hatch Waxman patent infringement suit brought against Actavis, Inc. In the suit, Actavis conceded infringement and argued that Valeant’s patents covering its new antidepressant, Aplenzin, were invalid as anticipated and/or obvious.

On October 16th 2013, the Federal Circuit affirmed the US District Court for the Southern District of Florida’s decision rejecting Actavis’ anticipation and obviousness defenses.

The Mayer Brown Intellectual Property litigation team was led by partners Terri Gillis (NY) and Tom Jenkins (Chicago) and included associates Clint Brannon (DC) and Eric Palmer (Chicago).